Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Status:
Recruiting
Trial end date:
2025-12-25
Target enrollment:
Participant gender:
Summary
To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of
refractory/relapsed peripheral T-cell lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Collaborators:
Dongguan People's Hospital Fujian Cancer Hospital Huizhou Municipal Central Hospital Shanxi Province Cancer Hospital Sun Yat-sen University The First Affiliated Hospital with Nanjing Medical University Zhangzhou Affiliated Hospital of Fujian Medical University